104681-92-7

Basic information

• Product Name: 4,4-dimethoxytetrahydro-2H-pyran-3-ol
• Synonyms: 4,4-dimethoxytetrahydro-2H-pyran-3-ol;EOS-60664
• CAS NO: 104681-92-7
• Molecular Formula: C₇H₁₄O₄
• Molecular Weight: 162
• EINECS: 200-589-5
• Mol File: 104681-92-7.mol

Chemical Properties

• Boiling Point: 236.8±40.0 °C(Predicted)
• Appearance: /
• Density: 1.13±0.1 g/cm3(Predicted)
• PKA: 13.21±0.40(Predicted)
• CAS DataBase Reference: 4,4-dimethoxytetrahydro-2H-pyran-3-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 4,4-dimethoxytetrahydro-2H-pyran-3-ol(104681-92-7)
• EPA Substance Registry System: 4,4-dimethoxytetrahydro-2H-pyran-3-ol(104681-92-7)

Safety Data

• Hazardous Substances Data: 104681-92-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
4,4-dimethoxytetrahydro-2H-pyran-3-ol is used as a synthetic intermediate for the production of various pharmaceuticals and agrochemicals. Its unique structure allows for the creation of a wide range of compounds with different therapeutic and pesticidal properties.
Used in Organic Chemistry Research:
DMPY-3-ol is utilized as a research compound in organic chemistry to explore its reactivity and potential use in the synthesis of complex organic molecules.
Used as an Antioxidant:
4,4-dimethoxytetrahydro-2H-pyran-3-ol is studied for its potential as an antioxidant, which could be beneficial in various applications where protection against oxidative stress is required.
Used for Antimicrobial Properties:
4,4-dimethoxytetrahydro-2H-pyran-3-ol has been investigated for its antimicrobial properties, suggesting its potential use in applications where control of microbial growth is necessary, such as in medical or food preservation contexts.
Used in Flavor and Fragrance Industry:
4,4-dimethoxytetrahydro-2H-pyran-3-ol is used as a flavor and fragrance ingredient in the food and cosmetics industries, capitalizing on its ability to impart specific scents or tastes to products.
Used in Cosmetics Industry:
In the cosmetics industry, DMPY-3-ol is employed for its potential to enhance the sensory experience of products, adding to their appeal through its contribution to fragrance profiles.

Upstream product

• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 67-56-1 methanol 
• 17327-22-9 4-methoxy-2,6-dihydropyran 
• 74-88-4 methyl iodide 
• 624734-19-6 3-fluorodihydro-2H-pyran-4(3H)-one 

Downstream Products

• 72250-01-2 3-hydroxy-tetrahydropyran-4-one 
• 1363380-59-9 cis-4-aminotetrahydropyran-3-ol 
• 693245-80-6 4,4-dimethoxy-5,6-dihydro-2H-pyran-3(4H)-one 
• 851916-41-1 (R)-3-methoxydihydro-2H-pyran-4(3H)-one 
• 624734-17-4 3-methoxydihydro-2H-pyran-4(3H)-one 
• 1232064-61-7 (3S,4S)-3-methoxytetrahydro-2H-pyran-4-amine 
• 1232064-59-3 (3S,4S)-3-methoxy-N-((S)-1-phenylethyl)tetrahydro-2H-pyran-4-amine 
• 1351450-56-0 3-benzyloxytetrahydropyran-4-one 
• 1351450-55-9 3-benzyloxy-4,4-dimethoxytetrahydropyran 
• 1096770-58-9 (3R,4S)-4-aminotetrahydro-2H-pyran-3-ol 
• 1268515-66-7 (3R,4S)-3-(benzyloxy)tetrahydro-2H-pyran-4-amine 
• 1268515-65-6 (3S)-3-(benzyloxy)-tetrahydro-4H-pyran-4-one 
• 1268515-64-5 (3S)-3-(benzylyoxy)-4,4-dimethoxytetrahydro-2H-pyran 
• 1268516-33-1 benzyl ((3S,4S)-4-hydroxytetrahydro-2H-pyran-3-yl)carbamate 

Relevant articles and documents

DIAZA-BENZOFLUORANTHRENE COMPOUNDS

Disclosed are a series of diaza-benzofluoranthrene compounds. The present invention particularly relates to a compound represented by formula (I), pharmaceutically acceptable salts or tautomers thereof.

BENZOISOQUINOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to substituted benzoisoquinolinone compounds, their salts, pharmaceutical compositions comprising them and their use in therapy. In particular, the invention is directed substituted benzoisoquinolinone compounds which are muscarinic M1 receptor positive allosteric modulators. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M1 receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M1 receptors are involved.

MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).

QUINAZOLINE COMPOUNDS USEFUL AS M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to compounds of Formula (I): (Formula (I)) and pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1, R7, R8, R9, R11, n and p are defined herein. The compounds of Formula (I) are M1 receptor positive allosteric modulators that are useful in the treatment of diseases in which the M1 receptor is involved, including Alzheimer's disease, schizophrenia, pain and sleep disorders. The invention also relates to pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier, and to methods of using the compounds of Formula (I) in the treatment of diseases mediated by the M1 receptor.

N-methyl tetrahydroquinoline M1 receptor positive allosteric modulators

The present invention is directed to N-methyl tetrahydroquinoline compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

FUSED CYCLOPENTYL ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). wherein: R0, R1, R2, R3, R4, R5, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I)

DIHYDROBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to dihydrobenzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease

N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to N-linked lactam compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

Heterocyclic amino acids for prostate cancer imaging

This invention relates to heterocyclic amino acid derivatives suitable for labeling or already labeled with 18F or 19F, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for imaging proliferative diseases.

PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as ALzheimer?s disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor